50th ICCAC, Boston, MA September 12-15, 2010

Conference Reports for NATAP


50th ICAAC Boston, MA September 12-15, 2010

	A Phase-Ib/IIa dose-escalation study for evaluation of the safety, tolerability, and pharmacokinetics of OBP-601 (4'-ethynyl-d4T, Festinavir) in treatment-experienced, HIV-1-infected patients - (10/13/10) ICAAC 2010 Report by David Margolis MD University of North Carolina - (10/04/10) Associations between Protease Inhibitors (PIs) and QTc and PR Interval Durations in the Strategies for Management of Antiretroviral Therapy (SMART) Trial - poster pdf attached - (10/04/10) Association Between Early Virologic Response and Immunologic Outcomes in Raltegravir-treated Patients: "Early vRNA decay is significantly correlated with greater increases in CD4 (absolute and %) change from baseline at Wk 96" - (10/04/10) HIV At ICAAC 2010: Complications & Co-Infections - Written by David H Shepp, MD Associate Professor of Medicine, Hofstra University School of Medicine Division of Infectious Diseases, North Shore University Hospital-Manhasset - (09/28/10) ICAAC PK Report - (09/26/10) Once-Daily Nevirapine XR Noninferior to Continued Twice-Daily Nevirapine - Written by Mark Mascolini - (09/19/10) Clinical, Virological and Immunological Characteristics of Patients With Discordant Phenotypic and Genotypic (Ultra-Deep Sequencing) Tropism Test Results: Analysis of Tropism Calls in MOTIVATE and 1029 (09/19/10) Use of Genotypic and Maraviroc (MVC) Clinical Trial Data to Develop Statistical Models for Predicting Response in a Treatment-Naive (TN) Population (09/19/10) 48-week resistance and efficacy subgroup analysis of once- versus twice-daily darunavir/ritonavir in ODIN (09/19/10) Comparison of Quest Diagnostics to Trofile and Trofile-ES Coreceptor Tropism Assays for Predicting Virologic Response to Maraviroc (MVC), a CCR5 Antagonist (09/19/10) Long-Term Outcome of Individuals Experiencing a Phenotypic Switch in HIV-1 Co-receptor Use in the MERIT Study (09/19/10) Raltegravir Pharmacokinetics during Pregnancy (09/16/10) Advanced Fibrosis Triples All-Cause Mortality With HCV and HIV - Written by Mark Mascolini - (09/16/10) CCR5 Antagonists Have No Special CD4-Boosting Power in Meta-Analysis (from Jules: I don't buy this) - Written by Mark Mascolini - (09/16/10) Once-Daily Nevirapine Noninferior to Twice-Daily Dose in Treatment Naive - Written by Mark Mascolini - (09/16/10) 48 Week Efficacy, Pharmacokinetics, and Safety of Once a Day 400 mg Nevirapine (Viramune) Extended Release Formulation for Treatment of Antiretroviral Naïve HIV-1 Infected Patients (09/15/10) Efficacy and Long-Term Safety of Tesamorelin (TH9507), a Growth Hormone-Releasing Factor (GRF) Analogue, in Sub-Populations of HIV-Infected Patients with Excess Abdominal Fat (09/15/10) Safety and Pharmacokinetics of BMS-650032 Following Multiple Ascending Doses for 14 Days in Healthy Subjects (09/15/10) The Single-Tablet Regimen Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate (EVG/COBI/FTC/TDF; "QUAD") Maintains a High Rate of Virologic Suppression, and Cobicistat (COBI) is an Effective Pharmacoenhancer Through 48 Weeks (09/15/10) Insulin Resistance Correlates With HCV Load and SVR in HCV/HIV-Coinfected - Written by Mark Mascolini - (09/15/10) GSK New NNRTI Selects No Resistance Mutations in 7 Days of Monotherapy - Written by Mark Mascolini - (09/15/10) Atazanavir Without Ritonavir Sustains Virologic Suppression 120 Weeks in ARIES - Written by Mark Mascolini - (09/15/10) Lipids Drop After Switch From ABC/3TC/Efavirenz to Atripla - Written by Mark Mascolini - (09/15/10) Final Results from Stage 1 of a Double-Blind, Placebo-Controlled Trial with TMC207 in Patients with Multi-Drug Resistant (MDR) Tuberculosis (TB) (09/15/10) Switching from ABC/3TC + Efavirenz [EFV] to TDF/FTC/EFV [Atripla, ATR] Reduces Cholesterol in Hypercholesterolemic Subjects: 24-Week Final Results of a Randomised Study (09/15/10) New GSK761 NNRTI (09/15/10) GSK2248761, an NNRTI with Activity Against Common NNRTI Resistance Mutants, Did Not Select for NNRTI Resistance Mutations in Two 7-Day Monotherapy Studies (09/15/10) TMC-278 Phase 3 ECHO/THRIVE Studies Resistance Profile Rilpivirine - Written by Mark Mascolini - (09/15/10) Gilead's Single-Tablet "Quad" HIV Regimen Maintains High Viral Suppression Through 48 Weeks in Phase II Study - press release (09/15/10) Four-Drug Single-Pill Antiretroviral Equivalent to Atripla at 48 Weeks - Written by Mark Mascolini - (09/15/10) High Rates of Bone Loss and Progression With HIV in Longitudinal Study - Written by Mark Mascolini - (09/15/10) Top Integrase Polymorphisms Do Not Confer Resistance to S/GSK1349572 or Raltegravir - Written by Mark Mascolini - (09/15/10) Raltegravir Re-Use Response After Failure Depends on Mutation Pattern - Written by Mark Mascolini - (09/15/10) Long-Term Outcomes Good After Coreceptor Switch in Maraviroc Failure - Written by Mark Mascolini - (09/15/10) Longer Antiretroviral Therapy Favors Return to Normal HDL-C - Written by Mark Mascolini - (09/15/10) Novel Mutations and Shifting Susceptibility to Darunavir and Tipranavir - Written by Mark Mascolini - (09/15/10) Characterization of the resistance profile of TMC278: 48-week analysis of the Phase III studies ECHO and THRIVE - (09/15/10) 24 Wk Efficacy and Safety of Transitioning Virologically Stable HIV-1 Patients from IR Nevirapine 200 mg BID to Nevirapine XR 400 mg QD (TRANxITION) - (09/15/10) Induction/Maintenance-Simplification: Sustained Virologic Efficacy of Atazanavir (ATV) Versus Atazanavir/Ritonavir (ATV/r), each in Combination with Abacavir/Lamivudine (ABC/3TC) over 120 Weeks: the ARIES Trial - (09/15/10) TMC-207 New TB Drug from Tibotec - New Drug Speeds Response in MDR TB - (09/15/10) Gilead's Single-Tablet "Quad" HIV Regimen Maintains High Viral Suppression Through 48 Weeks in Phase II Study - press release - (09/14/10) Two Doses of Hep A Vaccine in HIV+ Men Equivalent to One Dose in HIV- Men - Written by Mark Mascolini - (09/14/10) Reduction in Visceral Adipose Tissue (VAT) with Tesamorelin Correlates with Changes in Anthropometric, and Patient-Reported Outcome (PRO) Parameters in HIV+ Patients with Excess Abdominal Fat - (09/14/10) Comparison of 48 week efficacy and safety of 400mg QD nevirapine (NVP) extended release formulation (Viramune XR) versus 200mg BID nevirapine immediate release formulation (Viramune IR) in combination with emtricitabine/tenofovir in antiretroviral (ARV) naïve HIV-1 infected patients (VERxVE) - (09/14/10) Vitamin D Deficiency & Bone Loss in Europe - (09/14/10) ECG Abnormalities With PIs Versus NNRTIs in SMART Trial - Written by Mark Mascolini - (09/13/10) One Third on First-Line Antiretrovirals Have Clinically Significant Drug Interactions - Written by Mark Mascolini - (09/13/10) Maintenance With Raltegravir/Atazanavir Usually Effective for 48 Weeks (low troughs, a few viral rebounds) - Written by Mark Mascolini - (09/13/10) Staph Rate Falling in HIV+ Danes, But Still High vs General Population - Written by Mark Mascolini - (09/13/10)